Overview Therapeutic Collaborations Drug Targets Collaborations Research & Discovery Collaborations

Research & Discovery Collaborations

Compugen seeks to collaborate on its technology research programs in order to enhance development efforts and provide partners with an opportunity to benefit from the discoveries at an early stage. Current programs for which partners are sought are GPCR ligands, DAC Blockers, New indications for existing drugs, GeneVa™, Drug-induced Toxicity Biomarkers, Immunoassays, and Nucleic Acid Testing .

A sample list of our collaborations to date includes:

Pfizer
Compugen has a collaboration with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer. The discovery process, which is be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer. Following an evaluation period, Pfizer will have the right to exercise options for worldwide exclusive milestone and royalty bearing licenses to develop and commercialize the selected product candidates or further optimize them to obtain final potent, selective product candidates with favorable pharmacokinetic properties. | read more

Merck & Co., Inc.
Compugen has a collaboration with Merck & Co., Inc. targeted at predicting peptides likely to activate selected G-protein coupled receptors (GPCRs) and validating their agonistic activity. The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of therapeutic products | read more

Roche
Compugen has a collaborative discovery and license agreement with Roche for the identification and validation of genetic variations for the prediction of response to drugs used for the treatment of rheumatoid arthritis. Compugen plans to utilize its proprietary GeneVa™, platform to analyze DNA samples and clinical data provided by Roche in order to identify and validate non-SNP (Single Nucleotide Polymorphism) genetic variations that could serve as biomarkers for the predicted response or non-response to selected drugs for the treatment of rheumatoid arthritis. | read more

Teva Pharmaceutical Industries
Compugen has a collaboration agreement with Teva Pharmaceutical Industries Ltd. for the discovery of toxicity biomarkers for use in the preclinical stages of the drug development process. Though the collaboration focuses on the discovery of biomarkers for the early detection of nephrotoxicity, both parties have the option to pursue biomarkers for the detection of hepatotoxicity and/or cardiotoxicity in response to drug treatment. Compugen utilizes its proprietary computational tools, discovery engines and nucleic acid testing technologies for the purpose of predicting and validating toxicity biomarkers. Compugen's integrated analysis incorporates data derived from biological samples collected by Teva in a preclinical study designed specifically for this project, as well as Compugen's proprietary expression and clinical data. The collaboration agreement granted Teva a license to use any discovered markers for internal research and development activities. Compugen retained the commercialization rights for licensing such markers to other companies, as well as rights for internal use. | read more

Ortho-Clinical Diagnostics, a J&J company
Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, a Johnson & Johnson company, for the joint development of immunoassay-based diagnostic products using novel biomarkers discovered by Compugen and for the commercialization of those products by Ortho-Clinical Diagnostics. The collaboration combines Compugen's unique discovery capabilities provided by proprietary computational biology platforms with Ortho-Clinical Diagnostics' global development and commercialization strengths. | read more

Biosite
Biosite and Compugen have a collaboration agreement for the development and commercialization of immunoassay-based diagnostic products utilizing novel biomarkers discovered by Compugen through the use of its proprietary computational biology platforms. In March 2007, the agreement was expanded to enable Biosite to nominate its own targets or to select from Compugen’s increasing inventory of immunoassay biomarkers. The collaboration primarily targets cardiovascular disease and oncology. The collaboration combines Compugen's unique discovery capabilities with Biosite's expertise in rapid, high-affinity antibody development and successful commercialization of proprietary testing platforms consisting of both individual diagnostic markers and panels of markers. In April 2008, Compugen and Biosite entered a research and license option agreement. Under the agreement, Biosite will develop and select antibodies that bind to CGEN-144 to determine assay sensitivity and specificity in various disease states and as an addition to the current commercial Troponin I test. | read more

Siemens Healthcare Diagnostics
Siemens Healthcare Diagnostics and Compugen have a broad collaboration for the development and commercialization of immunoassay-based diagnostic products using novel biomarkers discovered by Compugen, with a focus on the cancer and cardiovascular fields. The agreement couples Compugen's unique discovery capabilities with Siemens Healthcare Diagnostics' proven ability and successful history in developing, manufacturing and worldwide marketing of diagnostic products. | read more

Collaboration with Known Clinic
Compugen has a collaboration agreement with a major US medical center to discover and validate novel biomarkers for diagnosing the presence of unstable atherosclerotic plaques in coronary artery disease and cerebrovascular disease. Compugen also expects to utilize its unique discovery engine approach to predict and validate biomarkers related to active atherosclerotic disease. Compugen's integrated analysis will incorporate data derived from biological materials provided by the known clinic, as well as Compugen's proprietary expression and clinical data. | read more